Tagged with ERS

Saudi Arabia Cooper Pharma, with its 90-year legacy, is at the forefront of transforming the pharmaceutical landscape in the Middle East. From localizing production in Saudi Arabia to pioneering collaborations with global institutions, the company is driving innovation in a rapidly evolving market. As Saudi Arabia’s Vision 2030 reshapes the future of…

Saudi Arabia Björn Bodenstein, Managing Director of Siemens Healthineers Saudi Arabia, explores the company’s commitment to supporting Saudi Vision 2030 through innovation, digital transformation, and strategic partnerships. By addressing healthcare accessibility, advancing sustainability, and nurturing local talent, Siemens Healthineers aims to play a transformative role in the Kingdom’s healthcare landscape.   Our…

Europe Dr Carolyn H. Rogers, Rushikesh S. Dasoondi and Dr Michael A. Roberts from UK and European intellectual property law firm Reddie & Grose LLP examine the intersection of personalised medicine and rare diseases and its implications for IP law.   Personalised medicine, also referred to as precision medicine, is an…

Global Since Paul Hudson took the helm in 2019, Sanofi has been in transformation mode, shedding its consumer health assets to focus on high-growth areas like oncology, immunology, and vaccines. With bold investments in R&D and AI-driven innovation, the French pharma is positioning itself as a pure-play biopharma leader. In conversation…

USA Since Christopher Viehbacher took the reins of Biogen in 2022, he has launched a USD 1 billion cost-cutting and priority refocusing plan, made significant deals, and launched the firm’s Alzheimer’s drug Legembi. But snags slowing the uptake of the Eisai-partnered med and the fall in sales of its multiple sclerosis…

Japan After 12 years at the helm, Takeda CEO Christophe Weber is stepping down, leaving behind a transformed company. Under his leadership, Japan’s biggest drugmaker expanded globally with the $62 billion acquisition of Shire, made waves with its dengue vaccine QDENGA, navigated the loss of exclusivity on its ADHD blockbuster, and…

Saudi Arabia Lyes Salah, General Manager of Amgen Saudi Arabia, delves into the company’s commitment to supporting Saudi Vision 2030 through innovation, strategic partnerships, and talent development. By advancing healthcare accessibility, fostering diversity, and driving digital transformation, Amgen plays a pivotal role in the Kingdom’s healthcare transformation.   Success is not an…

Saudi Arabia Amgad Talaat, Regional Cluster Head of EVA Pharma Saudi Arabia, delves into the company’s strategic expansion in the region, emphasizing investments in local manufacturing, innovation, and team development to align with Saudi Vision 2030. With a focus on addressing unmet medical needs and fostering partnerships, EVA Pharma is positioning itself…

Merck Over the course of its 350-year history, Merck KGaA has expanded from its base in Darmstadt, Germany to establish a strong presence in various markets across the globe. Last year, PharmaBoardroom spoke with Merck affiliate leaders in multiple geographies, uncovering their concerns and priorities as the firm pushed to recover…

Global In 2024, global biopharma faced a challenging landscape shaped by geopolitical tensions and cost containment measures in key markets. Despite these pressures, most major players perhaps surprisingly opted to retain their CEOs, focusing instead on reshaping management at other levels. Companies like Bayer underwent sweeping transformations, while others, such as…

USA While the year’s tally of green lights from the FDA’s Center for Drug Evaluation and Research (CDER) is lower than the previous year’s, 2024 saw several long-awaited therapies reach the finish line. Oncology remained the single largest focus area among last year’s endorsed therapies and as opposed to 2023 when…

China Since raising USD 289 million in its Spring 2020 Hong Kong IPO, InnoCare Pharma has had a remarkable rise. Led by a team of Big Pharma veterans and now also listed in Shanghai, the firm has secured regulatory approvals for its BTK inhibitor for haematological cancers in mainland China and…